2024
LB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changes
Swallow M, Chang J, Carlson K, Odell I, Girardi M. LB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changes. Journal Of Investigative Dermatology 2024, 144: s163. DOI: 10.1016/j.jid.2024.06.1104.Peer-Reviewed Original ResearchChart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart review
2021
Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review
Girardi M, Johnson A, Carlson K, Huang X, Corman S, Edmundson P, Kale H, Rusibamayila N, Foss F. Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review. Blood 2021, 138: 1405. DOI: 10.1182/blood-2021-151116.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaBody surface areaNew skin lesionsHalf of patientsExtracorporeal photopheresisT-cell lymphomaMallinckrodt PharmaceuticalsECP initiationClinical outcomesClinical trialsSkin lesionsInterim analysisRetrospective medical chart review studyResponse rateClinical Global Impressions-Improvement scoreDiagnosis of CTCLTreatment of CTCLClinical sitesStructured case report formRetrospective medical chart reviewMedical chart review studyReal-world clinical practiceSpeakers bureauStage IV diseaseAdvanced stage disease
2008
Nephrogenic Systemic Fibrosis: A Dermatologist’s Perspective
Girardi M. Nephrogenic Systemic Fibrosis: A Dermatologist’s Perspective. Journal Of The American College Of Radiology 2008, 5: 40-44. PMID: 18180008, DOI: 10.1016/j.jacr.2007.08.017.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisSystemic fibrosisDermatologist's perspectiveCutaneous manifestationsExtracorporeal photopheresisSevere contracturesSkin findingsCutaneous lesionsSubcutaneous indurationDiagnostic confirmationDifferential diagnosisSuch lesionsFibrosisLesionsPhotopheresisPatientsContracturePapulesPathogenesisIndurationPlaquesDiagnosis
2002
Transimmunization and the evolution of extracorporeal photochemotherapy
Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfusion And Apheresis Science 2002, 26: 181-190. PMID: 12126204, DOI: 10.1016/s1473-0502(02)00011-3.Peer-Reviewed Original ResearchConceptsDC/T cell interactionExtracorporeal photopheresisT cell responsesT cell interactionsT cell receptorPotent T cell responsesSpecific T cell responsesCutaneous T-cell lymphomaT cell-mediated diseaseDendritic cell therapyT cell reactionsT-cell lymphomaOrgan transplant rejectionT-cell malignanciesExtracorporeal photochemotherapySelective immunotherapyTransplant rejectionImmune effectsImmune responsePatients' leukocytesCell malignanciesEffective antigenCell therapyFirst FDACancer cells